Apellis Pharmaceuticals Revenue vs. Current Valuation

APLS Stock  USD 33.93  0.21  0.62%   
Based on Apellis Pharmaceuticals' profitability indicators, Apellis Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Apellis Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2014-06-30
Previous Quarter
199.7 M
Current Value
196.8 M
Quarterly Volatility
67.2 M
 
Yuan Drop
 
Covid
At this time, Apellis Pharmaceuticals' Price To Sales Ratio is comparatively stable compared to the past year. Days Sales Outstanding is likely to gain to 199.50 in 2024, whereas Operating Cash Flow Sales Ratio is likely to drop (1.57) in 2024. At this time, Apellis Pharmaceuticals' Income Tax Expense is comparatively stable compared to the past year. Interest Income is likely to gain to about 22 M in 2024, despite the fact that Operating Income is likely to grow to (491.3 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.990.8525
Fairly Up
Slightly volatile
For Apellis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Apellis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Apellis Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Apellis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Apellis Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Apellis Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.03)
Revenue Per Share
5.811
Quarterly Revenue Growth
0.783
Return On Assets
(0.16)
Return On Equity
(1.07)
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Apellis Pharmaceuticals Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Apellis Pharmaceuticals is the top company in revenue category among its peers. It also is the top company in current valuation category among its peers reporting about  10.89  of Current Valuation per Revenue. At this time, Apellis Pharmaceuticals' Total Revenue is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Apellis Revenue vs. Competition

Apellis Pharmaceuticals is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 411.65 Million. Apellis Pharmaceuticals totals roughly 396.59 Million in revenue claiming about 96% of equities under Health Care industry.

Apellis Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Apellis Pharmaceuticals

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
396.59 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Apellis Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
4.32 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Apellis Current Valuation vs Competition

Apellis Pharmaceuticals is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 5.57 Billion. Apellis Pharmaceuticals totals roughly 4.32 Billion in current valuation claiming about 78% of equities under Health Care industry.

Apellis Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Apellis Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Apellis Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Apellis Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Apellis Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.5 M-3.4 M
Operating Income-517.1 M-491.3 M
Income Before Tax-526.5 M-500.2 M
Total Other Income Expense Net-9.4 M-9.8 M
Net Loss-528.6 M-502.2 M
Net Loss-528.6 M-502.2 M
Net Loss-587 M-557.6 M
Income Tax Expense2.1 M2.2 M
Net Interest Income-8.6 M-9.1 M
Interest Income20.9 M22 M
Change To Netincome174.9 M183.7 M
Net Loss(4.45)(4.68)
Income Quality 1.13  0.65 
Net Income Per E B T 1.00  0.80 

Apellis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Apellis Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Apellis Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Apellis Pharmaceuticals' important profitability drivers and their relationship over time.

Use Apellis Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Apellis Pharmaceuticals Pair Trading

Apellis Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Apellis Pharmaceuticals position

In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Cap ETFs Thematic Idea Now

Small Cap ETFs
Small Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 167 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.